Accéder au contenu
MilliporeSigma

Caffeine and rolipram affect Smad signalling and TGF-β1 stimulated CTGF and transgelin expression in lung epithelial cells.

PloS one (2014-05-16)
Markus Fehrholz, Christian P Speer, Steffen Kunzmann
RÉSUMÉ

Caffeine administration is an important part of the therapeutic treatment of bronchopulmonary dysplasia (BPD) in preterm infants. However, caffeine mediated effects on airway remodelling are still undefined. The TGF-β/Smad signalling pathway is one of the key pathways involved in airway remodelling. Connective tissue growth factor (CTGF), a downstream mediator of TGF-β, and transgelin, a binding and stabilising protein of the cytoskeleton, are both regulated by TGF-β1 and play an important role in airway remodelling. Both have also been implicated in the pathogenesis of BPD. The aim of the present study was to clarify whether caffeine, an unspecific phosphodiesterase (PDE) inhibitor, and rolipram, a prototypical PDE-4 selective inhibitor, were both able to affect TGF-β1-induced Smad signalling and CTGF/transgelin expression in lung epithelial cells. Furthermore, the effect of transgelin knock-down on Smad signalling was studied. The pharmacological effect of caffeine and rolipram on Smad signalling was investigated by means of a luciferase assay via transfection of a TGF-β1-inducible reporter plasmid in A549 cells. The regulation of CTGF and transgelin expression by caffeine and rolipram were studied by promoter analysis, real-time PCR and Western blot. Endogenous transgelin expression was down-regulated by lentiviral transduction mediating transgelin-specific shRNA expression. The addition of caffeine and rolipram inhibited TGF-β1 induced reporter gene activity in a concentration-related manner. They also antagonized the TGF-β1 induced up-regulation of CTGF and transgelin on the promoter-, the mRNA-, and the protein-level. Functional analysis showed that transgelin silencing reduced TGF-β1 induced Smad-signalling and CTGF induction in lung epithelial cells. The present study highlights possible new molecular mechanisms of caffeine and rolipram including an inhibition of Smad signalling and of TGF-β1 regulated genes involved in airway remodelling. An understanding of these mechanisms might help to explain the protective effects of caffeine in prevention of BPD and suggests rolipram to be a potent replacement for caffeine.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Fluorure de phénylméthanesulfonyle, ≥98.5% (GC)
Sigma-Aldrich
Caféine, anhydrous, 99%, FCC, FG
Sigma-Aldrich
Fluorure de phénylméthanesulfonyle, ≥99.0% (T)
USP
Caféine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Caféine, powder, ReagentPlus®
Supelco
Caféine, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Caféine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Rolipram, solid, ≥98% (HPLC)
Supelco
Caféine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Caféine, Sigma Reference Standard, vial of 250 mg
Supelco
Schmelzpunktstandard 235-237°C, analytical standard
Supelco
Caféine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Caféine, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
Caféine, meets USP testing specifications, anhydrous
Supelco
Caféine, traceable to primary standards (LGC)
Sigma-Aldrich
Caféine, BioXtra
Caféine, European Pharmacopoeia (EP) Reference Standard
Caféine, European Pharmacopoeia (EP) Reference Standard